Highland raises $25M in venture round

Highland Therapeutics Inc. (Toronto, Ontario) raised $25 million in a venture round led by Eastern Capital. Highland CFO Nelson Isabel declined to disclose whether other investors participated.

Highland develops modified-release formulations of approved drugs that are intended for nighttime dosing with onset prior to awakening. Isabel said Highland plans to begin a pivotal trial "in the next month or so" of HLD-200, a modified-release formulation of the generic methylphenidate, to treat ADHD. By year end, the company plans to start a Phase IIb trial of HLD-100, a reformulated amphetamine, to treat ADHD. ...